Lilly raises guidance, launches Basaglar

Eli Lilly and Co. (NYSE:LLY) announced 2017 guidance in which it expects adjusted EPS of $4.05-$4.15 on revenue of $21.8-$22.3 billion. It expects mid-single-digit revenue growth driven by recent product launches, including diabetes drugs

Read the full 343 word article

User Sign In